TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29579617

Group type: EXPERIMENTAL
Intervention: Left ventricular endocardial pacing (LVEP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional cardiac resynchronization therapy (CRT)
Number of subjects: 118
Study: 29580174

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 214
Study: 29581087

Group type: EXPERIMENTAL
Intervention: Ostom-i alert sensor (wearable biosensor)
Number of subjects: 20
Study: 29581089

Group type: EXPERIMENTAL
Intervention: Better Nights, Better Days (BNBD) internet-based program
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 29581554

Group type: EXPERIMENTAL
Intervention: Atrial pacing at low HR (40 bpm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atrial pacing at middle HR (60 bpm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atrial pacing at high HR (90 bpm)
Number of subjects: 27
Study: 29582687

Group type: EXPERIMENTAL
Intervention: LARC
Number of subjects: 6744

Group type: COMPARATOR
Intervention: Non-LARC hormonal contraceptives
Number of subjects: 6744
Study: 29582894

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (fish oil)
Number of subjects: 50
Study: 29583084

Group type: EXPERIMENTAL
Intervention: Cervical smears performed by general practitioners (GPs)
Number of subjects: 90094

Group type: EXPERIMENTAL
Intervention: GPs performing smears
Number of subjects: 90094

Group type: EXPERIMENTAL
Intervention: Female GPs
Number of subjects: 90094
Study: 29584546

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks until disease progression/unacceptable toxicity
Number of subjects: 243
Study: 29584545

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 44
Study: 29584721

Group type: EXPERIMENTAL
Intervention: Lean diabetic group
Number of subjects: 6480

Group type: COMPARATOR
Intervention: Young group
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Elderly/AF group
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Ischemic group
Number of subjects: 6480

Group type: EXPERIMENTAL
Intervention: Metabolic group
Number of subjects: 6480
Study: 29587656

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 385
Study: 29587672

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment initiation
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Switching antidepressants
Number of subjects: 1402
Study: 29587677

Group type: EXPERIMENTAL
Intervention: OTS-GC-A24 cancer vaccine at 1 mg administered in 3-weekly (3w), 2-weekly (2w), and weekly (1w) cohorts.
Number of subjects: 24
Study: 29587682

Group type: EXPERIMENTAL
Intervention: Behaviorally based weight loss intervention (calorie reduction, exercise, behavior modification) over 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (participants who lost less than 5% weight)
Number of subjects: 0
Study: 29587709

Group type: EXPERIMENTAL
Intervention: S-TOFHLA
Number of subjects: 187
Study: 29587759

Group type: EXPERIMENTAL
Intervention: Preoperative anxiety measured with GAD-7 scale
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Preoperative pain intensity
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pain levels assessed on NRS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Regular pain medication intake
Number of subjects: 106
Study: 29587807

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group-based Acceptance and Commitment Therapy (ACT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition without bias modification
Number of subjects: 120
Study: 29587808

Group type: EXPERIMENTAL
Intervention: SRP in combination with 400 mg MTZ + 500 mg AMX, starting at the first SRP session (active phase group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SRP in combination with 400 mg MTZ + 500 mg AMX, starting after 3 months of its completion (healing phase group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: SRP-only (control group)
Number of subjects: 180
Study: 29587840

Group type: EXPERIMENTAL
Intervention: Timely diagnosis of PTB
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Prevention of secondary bacterial pneumonia by prophylactic management
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Optimization of the timing of cART initiation
Number of subjects: 359
Study: 29587881

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) delivered in deep inspiration breath-hold (DIBH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free breathing (FB)
Number of subjects: 0
Study: 29588126

Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine (NAC) 3600mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29588127

Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 755

Group type: COMPARATOR
Intervention: Opioid drugs
Number of subjects: 755
Study: 29588271

Group type: EXPERIMENTAL
Intervention: Exergame intervention (6-week training program, 3 sessions per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 24
Study: 29588273

Group type: EXPERIMENTAL
Intervention: BENECA mHealth system
Number of subjects: 20
Study: 29588286

Group type: EXPERIMENTAL
Intervention: Higher levels of plasma ceramides (16:0, 18:0, 20:0, 22:0)
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: Ceramide 16:0
Number of subjects: 2086
Study: 29588304

Group type: EXPERIMENTAL
Intervention: Very low-dose rivaroxaban added to DAPT (ASA + clopidogrel or ASA + ticagrelor)
Number of subjects: 40

Group type: COMPARATOR
Intervention: DAPT (ASA + clopidogrel or ASA + ticagrelor) without rivaroxaban
Number of subjects: 40
Study: 29588972

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 29589362

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21107
Study: 29590008

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice, e.g., docetaxel 75 mg/m2)
Number of subjects: 0
Study: 29590047

Group type: EXPERIMENTAL
Intervention: Translocation of a gut pathobiont
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29590311

Group type: EXPERIMENTAL
Intervention: Primaquine 0.5 mg/kg/day for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maternal levels of primaquine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of primaquine
Number of subjects: 20
Study: 29590318

Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: I-FABP
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 107
Study: 29590325

Group type: EXPERIMENTAL
Intervention: Breathalyzer-based eHealth system monitoring (Addiction Monitoring Index - AMI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low alcohol detection threshold (BrAC = 0.025 mg/l, BACSwe = 0.05‰ or US = 0.0053g/dl)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-resolution monitoring of sobriety
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMI-time profiles
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pattern of ignored tests
Number of subjects: 30
Study: 29590335

Group type: EXPERIMENTAL
Intervention: Raltegravir-containing regimen
Number of subjects: 30
Study: 29590358

Group type: EXPERIMENTAL
Intervention: Afirma Gene Expression Classifier (GEC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: ThyroSeq v2 next-generation sequencing
Number of subjects: 149
Study: 29590401

Group type: EXPERIMENTAL
Intervention: Intravenous injections of (S,S)-[11C]O-methylreboxetine ([11C]MRB) during hypoglycemia
Number of subjects: 9
Study: 29590547

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus Venetoclax
Number of subjects: 24
Study: 29592869

Group type: EXPERIMENTAL
Intervention: Monthly $60-per-child benefit
Number of subjects: 52000

Group type: EXPERIMENTAL
Intervention: Monthly $30-per-child benefit
Number of subjects: 52000

Group type: COMPARATOR
Intervention: No benefit
Number of subjects: 52000
Study: 29592876

Group type: EXPERIMENTAL
Intervention: Third-party fecal microbiota transplantation (FMT) capsules administered no later than 4 weeks after neutrophil engraftment.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Third-party fecal microbiota transplantation (FMT)
Number of subjects: 18
Study: 29593024

Group type: EXPERIMENTAL
Intervention: Hypocapnia via hyperventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Death and disability at 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance with the full measurement protocol
Number of subjects: 0
Study: 29593025

Group type: EXPERIMENTAL
Intervention: Heavy-stable trajectory
Number of subjects: 6820

Group type: EXPERIMENTAL
Intervention: Lean-marked increase trajectory
Number of subjects: 6820

Group type: COMPARATOR
Intervention: Lean-stable trajectory
Number of subjects: 6820
Study: 29593099

Group type: EXPERIMENTAL
Intervention: Pilaralisib tablets (400 mg once daily)
Number of subjects: 22
Study: 29593604

Group type: EXPERIMENTAL
Intervention: Behavioral Teacher Program
Number of subjects: 0
Study: 29594044

Group type: EXPERIMENTAL
Intervention: Ganetespib plus doxorubicin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 11
Study: 29594201

Group type: EXPERIMENTAL
Intervention: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG) after concurrent chemoradiation (CRT)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Lung FDG uptake (measured by SUVmax, SUVmean, SUVpeak, and GLG)
Number of subjects: 152
Study: 29594250

Group type: EXPERIMENTAL
Intervention: Durvalumab (DUR) combined with Cetuximab (CTX) and Radiotherapy (RT) (69.9 Gy/2.12 Gy in 33 fractions)
Number of subjects: 0
Study: 29594435

Group type: EXPERIMENTAL
Intervention: Higher serum carotenoids (α-carotene, β-cryptoxanthin, β-carotene, lycopene, lutein/zeaxanthin, total carotenoids)
Number of subjects: 3336

Group type: EXPERIMENTAL
Intervention: Lower serum RBP4, triglycerides, HOMA-IR, and BMI
Number of subjects: 3336
Study: 29594970

Group type: EXPERIMENTAL
Intervention: Anti-TNF agents (monotherapy or combination)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IBD patients (overall)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 90
Study: 29595064

Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax followed by the addition of chemotherapy; specific chemotherapy regimen not mentioned.
Number of subjects: 0
Study: 29595298

Group type: EXPERIMENTAL
Intervention: Cognitive and affective decision-making constructs related to SES
Number of subjects: 2015

Group type: EXPERIMENTAL
Intervention: SES-screening behavior relation
Number of subjects: 2015
Study: 29596029

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 127
Study: 29597136

Group type: EXPERIMENTAL
Intervention: IDQ-S Withdrawal Intolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDQ-S Lack of Cognitive Coping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDQ-S scales
Number of subjects: 0
Study: 29598824

Group type: EXPERIMENTAL
Intervention: Integrated reproductive, maternal, newborn, and child health intervention delivered by community health workers, which includes home-based antenatal care, post-natal care counseling, mobile application surveillance, Community-Based Integrated Management of Newborn and Childhood Illness, group antenatal and postnatal care, and Balanced Counseling Strategy for post-partum contraception.
Number of subjects: 0
Study: 29598861

Group type: EXPERIMENTAL
Intervention: Rapid Deployment Valves (RDV)
Number of subjects: 22062

Group type: COMPARATOR
Intervention: Conventional Biological Valves (CBV)
Number of subjects: 22062
Study: 29598891

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dialysis patients (ESRD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Open surgical treatment (all patients combined)
Number of subjects: 102
Study: 29598933

Group type: EXPERIMENTAL
Intervention: Early group (D2D time ≤60 min)
Number of subjects: 2761

Group type: COMPARATOR
Intervention: Delayed group (D2D time >60 min)
Number of subjects: 2761
Study: 29599068

Group type: EXPERIMENTAL
Intervention: Diuretic exposure
Number of subjects: 835

Group type: COMPARATOR
Intervention: No diuretic exposure (Control)
Number of subjects: 835
Study: 29599106

Group type: EXPERIMENTAL
Intervention: Thought Spot (Web- and mobile-based map)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 29599185

Group type: EXPERIMENTAL
Intervention: Telehealth intervention for COPD management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29599200

Group type: EXPERIMENTAL
Intervention: First-line treatment (specifics not provided)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (consolidation treatment)
Number of subjects: 1020
Study: 29599296

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS)
Number of subjects: 777

Group type: COMPARATOR
Intervention: No metabolic syndrome (non-MS)
Number of subjects: 777
Study: 29599530

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T-cell therapy
Number of subjects: 1
Study: 29599966

Group type: EXPERIMENTAL
Intervention: Icatibant treatment
Number of subjects: 342
Study: 29600778

Group type: EXPERIMENTAL
Intervention: AEMM maps (NOGA XP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: MRI tagging
Number of subjects: 33
Study: 29600824

Group type: EXPERIMENTAL
Intervention: Early concomitant vasopressin and norepinephrine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Norepinephrine monotherapy
Number of subjects: 82
Study: 29601256

Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV booster (1 dose for Group III, 2 doses for Groups VI and VII)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV (2 doses)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV
Number of subjects: 129
Study: 29601264

Group type: EXPERIMENTAL
Intervention: Total Nonnutritive Sweeteners (NNS)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Saccharin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Acesulfame potassium
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 125
Study: 29601268

Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and strength training, three 60-minute sessions per week from the 17th gestational week until delivery
Number of subjects: 47
Study: 29601591

Group type: EXPERIMENTAL
Intervention: Strengths-based case management intervention (SUCCESS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual services (control)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both arms (intervention and control)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 29601618

Group type: EXPERIMENTAL
Intervention: Pliaglis (self-occluding eutectic mixture of lidocaine and tetracaine)
Number of subjects: 581
Study: 29602324

Group type: EXPERIMENTAL
Intervention: Stepwise psychotherapy intervention
Number of subjects: 570

Group type: COMPARATOR
Intervention: Information session
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Anxious-preoccupied attachment
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fearful-avoidant attachment
Number of subjects: 570
Study: 29602473

Group type: EXPERIMENTAL
Intervention: Horizon stent graft (Endospan, Herzliya, Israel); 14F profile system, single access site
Number of subjects: 40
Study: 29602767

Group type: EXPERIMENTAL
Intervention: Dual loading antiplatelet therapy with aspirin and P2Y
Number of subjects: 5887
Study: 29602793

Group type: EXPERIMENTAL
Intervention: Cigarette smoking before and after meal intake
Number of subjects: 23

Group type: COMPARATOR
Intervention: No smoking (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of glucagon
Number of subjects: 23
Study: 29602794

Group type: EXPERIMENTAL
Intervention: NASH patients
Number of subjects: 28
Study: 29602842

Group type: EXPERIMENTAL
Intervention: Hyponatraemia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Impaired eGFR
Number of subjects: 405
Study: 29603015

Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523) at a recommended phase 2 dose of 600 mg BID
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ulixertinib (BVD-523)
Number of subjects: 105
Study: 29603017

Group type: EXPERIMENTAL
Intervention: Home-wearable light therapy for 60 min daily for 5 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Home-wearable light therapy
Number of subjects: 8
Study: 29603539

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29603764

Group type: EXPERIMENTAL
Intervention: Low dose lenalidomide (10 mg) plus dexamethasone (Rdex)
Number of subjects: 41
Study: 29604189

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 137
Study: 29605019

Group type: EXPERIMENTAL
Intervention: QoR-15 score classification
Number of subjects: 276
Study: 29605203

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat (using test VHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat
Number of subjects: 0
Study: 29605216

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Partially controlled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Controlled asthma
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: High ICS doses
Number of subjects: 203
Study: 29605405

Group type: EXPERIMENTAL
Intervention: Lifetime estrogen (E) exposure
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: E-free period
Number of subjects: 385
Study: 29605469

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM)
Number of subjects: 71483

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 71483

Group type: EXPERIMENTAL
Intervention: Long-term type 2 diabetes mellitus (≥20 years)
Number of subjects: 71483
Study: 29605494

Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with β-carotene
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with lutein/zeaxanthin
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Plasma proteins associated with β-cryptoxanthin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Plasma proteins associated with α-carotene
Number of subjects: 500

Group type: COMPARATOR
Intervention: Plasma proteins associated with lycopene
Number of subjects: 500
Study: 29605573

Group type: EXPERIMENTAL
Intervention: Integrated Nutrition Pathway for Acute Care (INPAC) including Canadian Nutrition Screening Tool and Subjective Global Assessment (SGA)
Number of subjects: 5030
Study: 29605813

Group type: EXPERIMENTAL
Intervention: Adolescents born very preterm with BPD and asthma symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (not explicitly defined in the abstract)
Number of subjects: 0
Study: 29606114

Group type: EXPERIMENTAL
Intervention: Supervised multi-station exercise program (7 stations with exercises of increasing difficulty)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Supervised multi-station exercise program
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Presence of more than three of five identified prognostic factors
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Presence of three or fewer of five identified prognostic factors
Number of subjects: 85
Study: 29606148

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (5 hours per week for 4 weeks via videoconference)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard Speech and Language Therapy (usual care)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 80
Study: 29606415

Group type: EXPERIMENTAL
Intervention: Alirocumab 75mg every 2 weeks (Q2W) added to statin therapy (atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day), with a potential increase to 150mg Q2W if LDL-C remains ≥100mg/dL at week 12.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with atorvastatin ≥10mg/day or rosuvastatin ≥5mg/day, with dose adjustment to achieve LDL-C <100mg/dL.
Number of subjects: 0
Study: 29606586

Group type: EXPERIMENTAL
Intervention: Larotrectinib, administered orally (capsule or liquid), twice daily on a continuous 28-day schedule, in increasing doses adjusted for age and bodyweight. Doses included 100 mg twice daily (cohort 1) and 150 mg twice daily (cohort 2).
Number of subjects: 24
Study: 29606665

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 579

Group type: COMPARATOR
Intervention: Combination ETN plus csDMARD
Number of subjects: 579
Study: 29607050

Group type: EXPERIMENTAL
Intervention: 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin for 12 weeks (UDCA-first group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA for 12 weeks (sitagliptin-first group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 900 mg UDCA
Number of subjects: 16
Study: 29607216

Group type: EXPERIMENTAL
Intervention: AT TORBI 709M IOL (Carl Zeiss Meditec AG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tecnis toric aspheric IOL (Abbot Medical Optics)
Number of subjects: 59
Study: 29608412

Group type: EXPERIMENTAL
Intervention: Academic Detailing intervention
Number of subjects: 87